AL-LAD
| Clinical data | |
|---|---|
| Other names | ALLAD; AllylLAD; Allyl-LAD; ALLYLAD; AllyLAD; ALLY-LAD; 6-Allyl-6-nor-LSD; 6-Allyl-6-nor-N,N-diethyllysergamide; 9,10-Didehydro-6-allyl-N,N-diethylergoline-8β-carboxamide |
| Routes of administration | Oral |
| Drug class | Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Onset of action | 15–20 minutes or hours |
| Duration of action | 6–8 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C22H27N3O |
| Molar mass | 349.478 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
AL-LAD, or ALLAD, also known as ALLY-LAD or as 6-allyl-6-nor-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is taken orally.
The drug interacts with serotonin and dopamine receptors and is known to act as an agonist of the serotonin 5-HT2A receptor similarly to LSD. AL-LAD produces psychedelic-like effects in animals. It is closely structurally related to LSD and to other psychedelic lysergamides such as ETH-LAD and PRO-LAD.
AL-LAD was first described in the scientific literature by 1976. Subsequently, it was described by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines i Have Known And Loved). AL-LAD was encountered as a novel designer recreational drug by 2015. The related drugs 1P-AL-LAD, 1cP-AL-LAD, and 1T-AL-LAD are thought to function as prodrugs of AL-LAD and have also been encountered as designer drugs in the 2020s.
- Drugs not assigned an ATC code